Skip to content

Menu

Venous Recanalization. Controlled

Home
Traversa
Team
News
Contact

About

Close Menu

March 2, 2022

Authority Magazine: An Interview With Luke Kervin

veinwaydev News

Health Tech: Jordan Pollack on How VeinWay’s Technology Can Make an Important Impact on Our Overall Wellness

AN INTERVIEW WITH LUKE KERVIN

Thank you to the MEDX Xelerator, Shai Policker, Yitzi Weiner, and Authority Magazine for this special opportunity.

https://medium.com/authority-magazine/health-tech-jordan-pollack-on-how-veinways-technology-can-make-an-important-impact-on-our-overall-733d7374c1b1

Recent Posts

Revealing Medical Advancements: Jordan Pollack, CEO of VeinWay Ltd | Med-Tech World 2023 Interview
VeinWay Closes Oversubscribed SAFE Round and Begins Series A Round
Interventional Vascular Specialists at Klinikum Hochsauerland, Clinic for Angiology/Clinic for Vascular Surgery in Germany Save Patient’s Arm in Second Human Compassionate Use of VeinWay’s Traversa for Venous Recanalization
VeinWay opens up the path to stop blood clots in underappreciated patients
First-in-Human Compassionate use of Veinway’s Traversa

Recent Comments

No comments to show.

Home
Traversa
Team
News
Contact

ABOUT

Veinway is a member of MEDX Xelerator, a medical device incubator backed by Boston Scientific, Sheba Medical Center, MEDX Ventures Group, Consensus Business Group (CBG), West Pharmaceuticals and The Portland Trust.

*Regulatory Approval Pending: This medical device has not yet received FDA clearance or CE marking.

© Veinway 2024

Site Powered By: SPinc

Ben Friesem CTO & Co-Founder

Ben joined VeinWay as co-founder to lead our R&D program. With 10 years of experience in medical device research and development, Ben brings to this position a significant track record in medical device innovation. His experience ranges from developing implants for minimally invasive spinal orthopedics (Nuvasive), basic academic research, to intravascular implant development in the field of structural heart. In his previous role as Senior Development Engineer at Restore Medical (first employee), Ben played a major role designing and developing the Contraband System, a nitinol based cardiovascular implant and subsequent transcatheter delivery system to treat CHF. He has taken products from the concept generation stage to clinical trials. He is listed on six issued and pending patents. He is a broadly experienced engineer skilled in nitinol and catheter design and has extensive knowledge of the start-up ecosystem. Ben holds a B.Sc. in Biomedical Engineering from the California Polytechnic State University (Cal Poly), a M.Sc. in Biotechnology Engineering from Ben Gurion University, and an MBA in Healthcare Innovation from Reichman University.

Jordan Pollack CEO & Co-Founder

Jordan holds a bachelor’s and master’s degree in biomedical engineering from the University of Michigan, and he recently completed (Sept 2021) his MBA in Healthcare Innovation from the Interdisciplinary College in Herzaliya, Israel. Jordan worked for four years at Boston Scientific in Maple Grove, MN, USA where he rotated through three different roles every eight months including Design Assurance (DA), Operations/Manufacturing Engineering, and Process Development (PD).

Prior to the rotational program, Jordan worked as an R&D engineer where he helped launch a Class III Combination Device through the FDA IDE submission and European Submissions to begin a clinical trial (Ranger, PTx coated balloon catheter). He also pioneered novel arterial below the knee model for stent delivery testing, released and updated BOM’s for finished assemblies and components, analyzed extensive medical literature to establish market credibility and build knowledge on the disease state, and devised R&D assessments on products to gather knowledge and data.